Delatestryl

Endo is a specialty pharmaceutical company that develops, manufactures, and markets a diverse range of branded and generic prescription pharmaceuticals. The company is the manufacturer of Delatestryl, a long-acting injectable form of testosterone enanthate used primarily for androgen replacement therapy in males. Endo maintains a significant presence in the urology, endocrinology, and medical aesthetics markets, alongside a robust sterile injectables business. Following a comprehensive financial restructuring in 2024, the company emerged as Endo, Inc., focusing on operational excellence and the delivery of life-enhancing medicines. Its portfolio includes well-known brands such as Xiaflex and a wide array of generic products across multiple therapeutic categories.